Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 12:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 2,795 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Combination Group Clear all

Conditions: Nonvalvular Atrial Fibrillation, Severe Degenerative Mitral Regurgitation
Interventions: MitraClip TMVR and Watchman LAAO; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Post Menopausal
Interventions: videodance, Brisk Walking, delayed entry control; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 50 Years to 65 Years · Female only
Enrollment: 168 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Healthy, Chronic Stable Illness
Interventions: casirivimab+imdevimab, Moderna mRNA-1273 vaccine; Drug · Biological
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 295 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 6
States / cities: Little Rock, Arkansas • Rogers, Arkansas • Hialeah, Florida + 3 more

Conditions: Pancreatic Cancer
Interventions: Oxaliplatin, Irinotecan, Leucovorin, 5FU, Stereotactic Body Radiotherapy (SBRT); Drug · Radiation
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 7
States / cities: Los Angeles, California • San Francisco, California • Stanford, California + 4 more

Conditions: Lymphoma, Follicular
Interventions: Ofatumumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, Prednisone or equivalent; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Pneumococcal Immunization
Interventions: PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccine, Rotarix, RotaTeq, Vaxelis vaccine, Varivax, Priorix, VAQTA, Havrix; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 42 Days to 89 Days
Enrollment: 2,360 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 103
States / cities: Birmingham, Alabama • Guntersville, Alabama • Oneonta, Alabama + 81 more

Conditions: Metastatic Breast Cancer, Tumor, Muscle Neoplasms, Chronic Pain
Interventions: Method(s)1 Attribution, Method(s)2 Attribution,; Drug
Lead sponsor: DR. DIANE CHISESI NFS. MD. PHD.; Other
Eligibility: 44 Years to 59 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Colorado Springs, Colorado

Conditions: Non-small Cell Lung Cancer
Interventions: PDR001, Cisplatin, Gemcitabine, Pemetrexed, Carboplatin, Paclitaxel, Canakinumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 5
States / cities: Fayetteville, Arkansas • Santa Monica, California • Stanford, California + 2 more

Conditions: Cystic Fibrosis
Interventions: LUM/IVA, activated smart device, de-activated smart device; Drug · Device
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 16 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 7
States / cities: Hartford, Connecticut • Washington D.C., District of Columbia • Orlando, Florida + 4 more

Conditions: PTSD
Interventions: fMRI - GE Medical System; Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 50 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Alcohol Use Disorder
Interventions: PST-APPLE Watch group, Education-only control group; Behavioral
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 25 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hypertension
Interventions: Aliskiren, Valsartan, Placebo for Aliskiren, Placebo for Valsartan; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 1,143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 4
States / cities: Newark, Delaware • Kansas City, Missouri • Camden, New Jersey + 1 more

Conditions: Physical Inactivity
Interventions: PA Education plus human and planetary health information, PA Education plus Our Voice citizen science; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 66 Years to 105 Years · Female only
Enrollment: 232 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Stanford, California

Conditions: Human Immunodeficiency Virus, STDs, Hepatitis, Viral, Human
Interventions: Tailored Cue Cards; Behavioral
Lead sponsor: RTI International; Other
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Raleigh, North Carolina

Conditions: ADHD
Interventions: Neurofeedback, Cognitive training; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 7 Years to 11 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Stanford, California

Conditions: Abortion Late, Pain
Interventions: Local anesthetic for tenaculum placement, Sham, Paracervical Block, Dilator Placement, Post-procedural assessment, Preprocedural pain control; Procedure · Behavioral · Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older · Female only
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 2
States / cities: San Diego, California

Conditions: Obesity
Interventions: Velneperit 400 mg, Orlistat 120 mg, Orlistat Placebo, Velneperit Placebo, Reduced Calorie Diet; Drug · Other
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 486 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 25
States / cities: Santa Rosa, California • Waterbury, Connecticut • Clearwater, Florida + 22 more

Conditions: Rhinitis, Conjunctivitis
Interventions: Grass-SPIRE, Placebo; Drug
Lead sponsor: Circassia Limited; Industry
Eligibility: 12 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2016
U.S. locations: 2
States / cities: Canton, Ohio • Cincinnati, Ohio

Conditions: Stroke, Stroke (CVA) or Transient Ischemic Attack, Stroke Ischemic, Stroke Gait Rehabilitation, Balance Deficits
Interventions: Combined (Robotic balance training and high-definition transcranial direct current stimulation), Standard of Care Balance Training; Device · Other
Lead sponsor: Kessler Foundation; Other
Eligibility: 18 Years to 75 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: West Orange, New Jersey

Conditions: Drug-Induced Liver Injury
Interventions: Moxifloxacin (Avelox, BAY12-8039), Amoxicillin, Amoxicillin plus clavulanic acid, Cefuroxime, Clarithromycin, Doxycycline, Levofloxacin, Telithromycin; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 1,299,056 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 1
States / cities: Many Locations, Delaware

Conditions: Type 1 Diabetes, Adolescent Behavior
Interventions: Mind-body skills, Diabetes education; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 15 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Indianapolis, Indiana

Conditions: Coronary Artery Disease
Interventions: Medical/Behavioral therapy, Standard of Care, Registry; Other
Lead sponsor: Emory University; Other
Eligibility: 21 Years to 90 Years
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 5
States / cities: Atlanta, Georgia

Conditions: Asthma
Interventions: Fluticasone Furoate/GW642444, Fluticasone propionate; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 503 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 18
States / cities: Oxford, Alabama • Huntington Beach, California • Mission Viejo, California + 15 more

Conditions: Locally Advanced Solid Tumor, Metastatic Cancer, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Mesothelioma, Melanoma, Head and Neck Cancer
Interventions: CTX-471, Pembrolizumab (KEYTRUDA®); Drug
Lead sponsor: Compass Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 10
States / cities: Ocala, Florida • Port Saint Lucie, Florida • Boston, Massachusetts + 6 more

Search by objective public record fields.

Watchman for Patients With Atrial Fibrillation Undergoing Transcatheter Mitral Valve Repair (WATCH-TMVR)

Adherence and Health Effects of Video Dance in Postmenopausal Women

COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers

Phase 3 Study of FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer

Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, Predisolone) in Follicular Lymphoma (FL) Patients

Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

Anastrozole Adjuvant Trial - Study of Anastrozole Compared to NOLVADEX (Tamoxifen Citrate) for Adjuvant Treatment of Early Breast Cancer Clinical Studies), Adjunct Cytotoxic Chemotherapy and Malignant Joint Tumor

PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients

A Pilot Study to Evaluate the Use of Smart Adherence Technology to Measure Lumacaftor/Ivacaftor Adherence in CF Subjects Homozygous for the F508del CFTR Mutation

Neurofeedback With Real-Time fMRI for Treatment of PTSD

Pilot Trial to Evaluate PROblem Solving Therapy and APPLE Watch for College Students

Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus

Testing Multi-Level Remote Physical Activity Interventions in a National Sample of Older Women: The WHISH EnCore Trial

Computer-Assisted Tailored Cue-card Health [CATCH] Study

A Novel fNIRS Neurofeedback Intervention for Enhancement of Working Memory in Attention Deficit Hyperactivity Disorder (ADHD)

Paracervical Block for Pain Control With Osmotic Dilator Placement

Double-Blind, Multi-Center, Randomized Study to Assess the Efficacy and Safety of Velneperit (S-2367) and Orlistat Administered Individually or Combined With a Reduced Calorie Diet (RCD) in Obese Subjects

Efficacy and Safety of Grass-SPIRE Registration Study

Neuromodulation-Enhanced Use of RObotic BALANCE Training to Improve Balance Function in Individuals With Stroke

Risk of Acute Liver Injury in Users of Antimicrobials

Incorporating Mind-body Skills With Diabetes Education in Adolescents With Type 1 Diabetes

The Precision CAD Trial

Fluticasone Furoate/GW642444 Inhalation Powder Long-Term Safety Study

Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies